Intensive induction therapy with FLAG-idarubicin-venetoclax for fit older high-risk patients with acute myeloid leukemia

Puntos clave

• To evaluate the efficacy of FLAG-idarubicin-venetoclax induction therapy in fit older patients with high-risk acute myeloid leukemia.
• Administered FLAG-idarubicin-venetoclax regimen to fit older patients.
• Monitored treatment outcomes and patient responses post-therapy.
• Compared findings with conventional chemotherapy outcomes when applicable.
• Increased remission rates observed compared to standard treatments.
• Improved overall survival in the study population.
• Fewer side effects reported with this combination therapy.